
CLAIMS

~~We claim:~~

1. A pharmaceutical composition comprising



(Conjugate **57**) or a pharmaceutically acceptable salt thereof, acetate buffer, mannitol, and solutol.

2. The pharmaceutical composition of claim 1, wherein the acetate buffer has a strength of at least 30mM.

3. The pharmaceutical composition of claim 1, wherein the acetate buffer has a strength of at least 40mM.

4. The pharmaceutical composition of claim 1, wherein the mannitol has a concentration of about 5%.

5. The pharmaceutical composition of claim 1, wherein the solutol has a concentration of about 2%.

6. Use of ~~A method of treating tumor comprising administering~~ Conjugate **57** or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of tumor in ~~to~~ a subject ~~in need thereof~~, wherein the dose of Conjugate **57** is based on the body surface area (BSA) of the subject, and wherein the dose of Conjugate **57** is 8.8 mg/m^2 or less than 8.8 mg/m^2.

7. The ~~method~~ use of claim 6, wherein the tumor is a neuroendocrine tumor (NET).

8. The ~~method~~ use of claim 6, wherein the tumor selected from the group consisting of gastroenteropancreatic (GEP), gastrointestinal (GI), pancreatic, lung, prostate, and thymus neuroendocrine tumor.

9. The ~~method~~ use of claim 6, wherein the tumor is small cell lung cancer (SCLC) or large cell neuroendocrine carcinoma (LCNEC) of the lung.

10. Conjugate 57 or a pharmaceutically acceptable salt thereof, for use in therapy.